Speech-based Assessment of Relapse Risk in People With Psychosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorPhilipp Homan

About this trial

This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis. Over 12 months, patients at risk of relapse and healthy controls will provide weekly speech recordings and self-report data for automated analysis. Risk scores will be stored but not shared with treating clinicians. Independent clinical evaluations ensure data quality and validation. The study lays the foundation for future Clinical Decision Support System (CDSS) research and explores novel speech markers for relapse prediction while minimizing participant burden.

Eligibility criteria

Qualifiers

Between 18 and 65 years old.

Subjects must be able to provide informed consent (IC).

Participants must have provided signed informed consent prior to enrollment.

Participants should not take prescription drugs regularly.

Disqualifiers

Any history of major diseases (e.g., cardiovascular, neurological, metabolic, renal, hepatic, respiratory or speech disorders).

Recreational drug use or psychiatric disorders due to use of alcohol.

Depression, anxiety, or other psychiatric disorders.

Family history of depression, anxiety, or other psychiatric disorders.

Trial design

Treatments tested in this trial

  • Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.

Treatment groups

360 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Philipp Homan

Lead sponsor

University of Zurich

Sponsor institution